Case Report
Korean J Hematol 2005; 40(2):
Published online June 30, 2005
https://doi.org/10.5045/kjh.2005.40.2.124
© The Korean Society of Hematology
알파 인터페론 불응성 만성골수성백혈병 환자에서 Imatinib Mesylate 치료 후 골수섬유화의 반전 1예
김연성, 김태훈, 김원철, 전연주, 길욱현, 이혜경, 김영식, 노상영, 조석구
가톨릭대학교 의과대학, 혈액종양내과학교실, 임상병리과학교실
Reversal of Marrow Fibrosis Following Imatinib Mesylate Therapy in a Patient with Chronic Myelogenous Leukemia Who Was Refractory to Interferon-Ձ
Bone marrow fibrosis is associated with a poor prognosis in those patients with chronic myelogenous leukemia (CML). It is present at the initial diagnosis as well as during CML transformation. Although the effect of interferon-Ձ therapy on marrow fibrosis has been controversial, imatinib mesylate has shown significant activity to reduce the CML-associated bone marrow fibrosis as well as the Philadelphia chromosome-positive cells. We report here on a case of the reversal of marrow fibrosis after imatinib mesylate therapy in a 67 year-old female patient suffering with CML that was refractory to interferon-Ձ.
Keywords Imatinib mesylate, Chronic myelogenous leukemia, Marrow fibrosis
PDF
Standard view
Export citation
Share Article
Case Report
Korean J Hematol 2005; 40(2): 124-128
Published online June 30, 2005 https://doi.org/10.5045/kjh.2005.40.2.124
Copyright © The Korean Society of Hematology.
알파 인터페론 불응성 만성골수성백혈병 환자에서 Imatinib Mesylate 치료 후 골수섬유화의 반전 1예
김연성, 김태훈, 김원철, 전연주, 길욱현, 이혜경, 김영식, 노상영, 조석구
가톨릭대학교 의과대학, 혈액종양내과학교실, 임상병리과학교실
Reversal of Marrow Fibrosis Following Imatinib Mesylate Therapy in a Patient with Chronic Myelogenous Leukemia Who Was Refractory to Interferon-Ձ
Yeon Seong Kim, Tae Hun Kim, Won Chul Kim, Youn Joo Jeon, Uk Hyun Kil, Hae Kyung Lee, Yeong Sik Kim, Sang Young Rho, Seok Goo Cho
Division of Hematology, Department of Internal Medicine, Clinical Pathology, College of Medicine,The Catholic University of Korea, Seoul, Korea
Abstract
Bone marrow fibrosis is associated with a poor prognosis in those patients with chronic myelogenous leukemia (CML). It is present at the initial diagnosis as well as during CML transformation. Although the effect of interferon-Ձ therapy on marrow fibrosis has been controversial, imatinib mesylate has shown significant activity to reduce the CML-associated bone marrow fibrosis as well as the Philadelphia chromosome-positive cells. We report here on a case of the reversal of marrow fibrosis after imatinib mesylate therapy in a 67 year-old female patient suffering with CML that was refractory to interferon-Ձ.
Keywords: Imatinib mesylate, Chronic myelogenous leukemia, Marrow fibrosis
Previous Article
Article Tools
Stats or Metrics
Share this article on
Related articles in BR
-
A case of subdural hematoma in patient with chronic myeloid leukemia treated with high-dose imatinib mesylate
Min Sik Kim, Dong Hyun Lee, Yu Rim Lee, Dong Kyun Kim, Suk Hyang Bae, Jin Yeon Hwang, Kyung A Kwon, Suee Lee, Jin Yeong Han, Ki Uk Kim, and Sung-Hyun Kim
Korean J Hematol 2010; 45(1): 73-75 -
Characteristics of hematologic malignancies with coexisting t(9;22) and inv(16) chromosomal abnormalities
Eunhee Han, Hyeyoung Lee, Myungshin Kim, Yonggoo Kim, Kyungja Han, Sung-Eun Lee, Hee-Je Kim, and Dong-Wook Kim
Blood Res 2014; 49(1): 22-28 -
Mutation of the N-ras Gene in a Patient Suffering from the Blast Phase of Chronic Myelogenous Leukemia
Sung Heon Song, Young Wook Roh, Yong Woo Ahn, Yeon Jae Kim, Young Sang Byoun, Ji Young Choi, Deok Won Hwang, Byoung Bae Park, Jung Hye Choi, In Soon Kim, Byoung Kook Kim, Young Yiul Lee
Korean J Hematol 2009; 44(2): 100-103
